ArticleDrug and alcohol dependence2016
Receipt of pharmacotherapy for opioid use disorder by justice-involved U.S. Veterans Health Administration patients.
Article in Drug and alcohol dependence, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Routes of non-traditional entry into buprenorphine treatment programs.Substance abuse treatment, prevention, and policy · 2020Pooled it
- Differences in benefits of office based opioid treatment: Secondary analyses across sub-groups in the PROUD randomized controlled implementation trial.Addiction (Abingdon, England) · 2026Trial
- Extended-release naltrexone opioid treatment at jail reentry (XOR).Contemporary clinical trials · 2016Trial
- Retention on Buprenorphine for Opioid Use Disorder in Justice-Involved Individuals: A Retrospective Cohort Study.Behavioral sciences (Basel, Switzerland) · 2026Article
- Article
- Characteristics of Veterans Receiving Medication for Opioid Use Disorder: An Observational Cohort Study.Journal of general internal medicine · 2025Article
- Receipt of medications for opioid use disorders among veterans by race/ethnicity and legal involvement: an observational study of electronic health records.Health & justice · 2025Article
- Receipt of medications for opioid use disorder among rural and urban veterans health administration patients.Drug and alcohol dependence reports · 2025Article
- Improving access to buprenorphine for rural veterans in a learning health care system.Health services research · 2024Article
- Article
- Association of polysubstance use disorder with treatment quality among Medicaid beneficiaries with opioid use disorder.Journal of substance abuse treatment · 2023Article
- Enhancing community integration after incarceration: findings from a prospective study of an intensive peer support intervention for veterans with an historical comparison group.Health & justice · 2022Article
- Perioperative Management of Buprenorphine/Naloxone in a Large, National Health Care System: a Retrospective Cohort Study.Journal of general internal medicine · 2022Article
- Association between clinically recognized suicidality and subsequent initiation or continuation of medications for opioid use disorder.Drug and alcohol dependence · 2022Article
- A national survey of barriers and facilitators to medications for opioid use disorder among legal-involved veterans in the Veterans Health Administration.Substance abuse · 2022Article
- Legal System Involvement and Opioid-Related Overdose Mortality in U.S. Department of Veterans Affairs Patients.American journal of preventive medicine · 2022Article
- Fluctuations in barriers to medication treatment for opioid use disorder prescribing over the course of a one-year external facilitation intervention.Addiction science & clinical practice · 2021Article
- The Importance of Learning Health Systems in Addressing the Opioid Crisis.Journal of general internal medicine · 2020Article
- The association of criminal justice supervision setting with overdose mortality: a longitudinal cohort study.Addiction (Abingdon, England) · 2020Article
- Capsule Commentary on Finlay et al., Barriers to Medications for Opioid Use Disorder Among Veterans Involved in the Legal System: a Qualitative Study.Journal of general internal medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 1 country.
Funding
Abstract
backgroundPharmacotherapy - methadone, buprenorphine, or naltrexone - is an evidence-based treatment for opioid use disorder, but little is known about receipt of these medications among veterans involved in the justice system. The current study examines receipt of pharmacotherapy for opioid use disorder among veterans with a history of justice involvement at U.S. Veterans Health Administration (VHA) facilities compared to veterans with no justice involvement.
methodsUsing national VHA clinical and pharmacy records, we conducted a retrospective cohort study of veterans with an opioid use disorder diagnosis in fiscal year 2012. Using a mixed-effects logistic regression model, we examined receipt of pharmacotherapy in the 1-year period following diagnosis as a function of justice involvement, adjusting for patient and facility characteristics.
resultsThe 1-year rate of receipt for pharmacotherapy for opioid use disorder was 27% for prison-involved veterans, 34% for jail/court-involved veterans, and 33% for veterans not justice-involved. Compared to veterans not justice-involved, those prison-involved had 0.75 lower adjusted odds (95% confidence interval [CI]: 0.65-0.87) of receiving pharmacotherapy whereas jail/court-involved veterans did not have significantly different adjusted odds.
conclusionsTargeted efforts to improve receipt of pharmacotherapy for opioid use disorder among veterans exiting prison is needed as they have lower odds of receiving these medications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.